InSysBio to participate in ASCPT 2022

February 24, 2022

February 24, 2022

InSysBio announces its participation in ASCPT 2022 Annual Meeting which is to be held virtually March 16-18, 2022. InSysBio is going to give a talk in frames of its Micro-Theater Session with live Q&A which is scheduled for 3:30 PM ET, Thursday, March 17th. The talk by Oleg Demin and Alexander Stepanov will cover the topic, "Online databases collecting and processing publicly available data can help in calibration and validation of QSP models". InSysBio team will also present two posters in frames of the conference, namely:

Wednesday, March 16

  • P-169 "QSP model of human erythropoiesis under chemotherapy" by Alexander Stepanov, Galina Lebedeva

Wednesday, March 16, 5:38 PM - 5:42 PM ET

(Poster Walk: Model Informed Drug Development: Novel Applications Across Therapeutic Areas)

  • PW-014 (Presentation) "Application of semi-mechanistic mathematical modeling to optimize lymphodepletion regimen administered before infusion of genetically modified T cells" by Oleg Demin Jr1, Galina Kolesova1, Antonina Nikitich1, Ioanna Eleftheriadou2, Stefan Zajic2, Ionel Mitrica3, Alexandra Gyurdieva2, Lourdes Cucurull-Sanchez4

Affiliation: (1) InSysBio, Moscow, Russia; (2) GlaxoSmithKline, Upper Providence, PA, USA; (3) GlaxoSmithKline, Zug, Switzerland; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK.

Thursday, March 17, 3:30 PM ET

  • Micro-Theater Session "Online databases collecting and processing publicly available data can help in calibration and validation of QSP models" by Oleg Demin, Alexander Stepanov

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit